Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate in High-Risk, Early-Stage ER-positive, HER2-negative Breast Cancer By Ogkologos - February 12, 2025 1099 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 7FL and KEYNOTE-756 studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO launches new principles for humanising scientific reporting to strengthen the communication of cancer research Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume mHNPC, but Without Clear Benefit Over Enzalutamide in Biomarker-Unselected Population FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma MOST POPULAR ESMO Welcomes European Parliament (EP) report on Psychosocial Risks (PSR) at... September 3, 2026 A “Living Medicine:” Engineered E. coli Shrink Tumors in Mice December 11, 2024 How I’m Working to Erase the Stigma of Lung Cancer: A... November 22, 2023 Trastuzumab Deruxtecan Demonstrates Efficacy in HER2-positive and HER2-low Advanced Gastric Cancer July 6, 2021 Load more HOT NEWS Patient Exposure to Anticancer Drugs Subsequently Withdrawn from the FDA Accelerated... Significant Interaction Between a Chemotherapy Benefit and Menopausal Status Found in... Tyrosine Kinase Inhibitor Prolongs Progression-Free Survival in Rare Neuroendocrine Tumours [ESMO... Phlebotomist Breaks Into Ballet Performance In The Middle Of The Hospital
